Pfizer’s Stock Is Down 44% YTD As Woes Continue

Pfizer's shares plunged on Friday after the drugmaker halted the trial of its twice-daily obesity drug.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.